Corticosteroids

Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection
Zhenyu Zhong, Weiting Liao, Lingyu Dai, Xiaojie Feng, Guannan Su, Yu Gao, Qiuying Wu, Peizeng Yang

Annals of the Rheumatic Diseases Apr 2022, 81 (4) 584-591; DOI: 10.1136/annrheumdis-2021-221650
Glucocorticoid withdrawal in lupus – to do or not to do?
Nupoor Acharya

Annals of the Rheumatic Diseases Mar 2022, 81 (3) e44; DOI: 10.1136/annrheumdis-2020-217261
Comments on the article: “Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial”
Mohammad Reza Mousavi, Erfan Taherifard

Annals of the Rheumatic Diseases Mar 2022, 81 (3) e46; DOI: 10.1136/annrheumdis-2020-217287
Response to: ‘Dupilumab as a potential steroid-sparing treatment for IgG4-related disease’ by Della-Torre et al
Rachel S Simpson, Jason K Lee

Annals of the Rheumatic Diseases Feb 2022, 81 (2) e25; DOI: 10.1136/annrheumdis-2020-216955
Response to: ‘Correspondence on: ‘Dupilumab as a novel steroid-sparing treatment for IgG4-related disease’ by Simpson et al’ by Ebbo et al
Rachel S Simpson, Jason K Lee

Annals of the Rheumatic Diseases Feb 2022, 81 (2) e27; DOI: 10.1136/annrheumdis-2020-217029
Response to : ‘Interleukin-4 as a emerging target for IgG4-related disease’ by Akiyama et al
Rachel S Simpson, Jason K Lee

Annals of the Rheumatic Diseases Feb 2022, 81 (2) e29; DOI: 10.1136/annrheumdis-2020-216977
What is the starting dose of steroid prescribed by rheumatologist in the management of polymyalgia rheumatica?
Jean Jacques Dubost, Bruno Pereira, Angelique Fan, Martin Soubrier

Annals of the Rheumatic Diseases Aug 2021, 80 (8) e133; DOI: 10.1136/annrheumdis-2019-216050
Correspondence to ‘Time to change the primary outcome of lupus trials’
Shereen Oon, Molla Huq, Mandana Nikpour

Annals of the Rheumatic Diseases Jul 2021, 80 (7) e109; DOI: 10.1136/annrheumdis-2019-216113
Eric Bywaters a life story: 1 June 1910 to 2 April 2003
David Isenberg

Annals of the Rheumatic Diseases Aug 2020, 79 (8) 996-998; DOI: 10.1136/annrheumdis-2020-217153
Longitudinal versus cross-sectional IL-6 measurements in tocilizumab-treated GCA. Response to: ‘Analysis of IL-6 measurement in GCA patients treated with tocilizumab should consider concomitant treatment with prednisone’ by Samson and Bonnotte
Christoph T Berger, Thomas Daikeler

Annals of the Rheumatic Diseases Aug 2020, 79 (8) e103; DOI: 10.1136/annrheumdis-2019-215729

Main menu

Corticosteroids

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Corticosteroids

Pages